Innovent Biologics (IVBXF) Revenue
Innovent Biologics Revenue
Innovent Biologics had a revenue of 8.50B in the quarter ending Jun 30, 2026, with 19.90%. This bring the company's revenue in the last twelve months to 15.59B, Increased 19.52%. In the fiscal year ending Dec 31, 2025, Innovent Biologics had annual revenue of 13.04B with 38.42% growth.
- Revenue (ttm)
- 15.59B
- Revenue Growth
- 42.21%
- P/S Ratio
- 1.36
- Revenue/Employee
- $1,489,779
- Employees
- 8,754
- Market Cap
- $17.76B
Revenue Chart
Innovent Biologics Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.04B | 3.62B | 38.42% |
| Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
| Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
| Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
| Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
| Dec 31, 2020 | 3.84B | 2.80B | 266.94% |
| Dec 31, 2019 | 1.05B | 1.04B | 10953.34% |
| Dec 31, 2018 | 9.48M | -9.06M | -48.88% |
| Dec 31, 2017 | 18.54M | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.